| Audience | Patients considering commercial CBG products, primary care and cannabis clinicians counseling on minor cannabinoids, and researchers tracking cannabinoid pharmacology |
| Primary Topic | A single ascending-dose, randomized, double-blind, placebo-controlled human laboratory study of oral cannabigerol (CBG) safety, pharmacodynamics, and pharmacokinetics in 12 healthy adults, published in the Journal of Pharmacology and Experimental Therapeutics, July 2026 |
| Source | Read the study on PubMed |
Oral Cannabigerol (CBG): What a New Human Safety Study Actually Found
In a single ascending-dose laboratory study, 12 healthy adults received oral cannabigerol (CBG) at 0, 25, 50, 100, and 200 milligrams. No drug-related adverse events occurred, subjective and cognitive effects were minimal, liver function stayed within normal limits, and plasma CBG levels rose in a dose-orderly but individually variable way.
| Study Type | Single ascending-dose, randomized, double-blind, placebo-controlled human laboratory study |
| Population | 12 healthy adults |
| Intervention | Oral CBG isolate in medium-chain triglyceride oil at 25, 50, 100, and 200 mg, in an ascending dose sequence |
| Comparator | Placebo (matched oil), randomly inserted within each participant’s ascending dose sequence |
| Blinding | Double-blind, maintained by standardizing flavor and solution volume across doses |
| Assessment Windows | Baseline and 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours after dosing |
| Outcomes Measured | Adverse events; subjective, cognitive, and physiological (pharmacodynamic) responses; plasma CBG pharmacokinetics; liver function tests |
| Liver Monitoring | Checked at baseline and again after the two highest doses (100 mg and 200 mg) |
| Safety Result | No drug-related adverse events at any dose; liver function tests never exceeded the upper limit of normal |
| Pharmacodynamic Result | Minimal subjective effects: decreased self-rated Jittery and Active at 50 mg, decreased Calm at 100 mg, increased Appetite at 200 mg |
| Pharmacokinetic Result | Plasma CBG concentrations rose in a dose-orderly pattern with substantial individual variability |
| Research Site | Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, with collaborators at the University of Maryland, University of Colorado, and University of Virginia |
| Journal | Journal of Pharmacology and Experimental Therapeutics |
| Published | July 11, 2026 (online ahead of print) |
| DOI | 10.1016/j.jpet.2026.104984 |
| PMID | 42575778 |
Researchers at the Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit, working with colleagues at the University of Maryland, University of Colorado, and University of Virginia, enrolled 12 healthy adults in a single ascending-dose study of oral CBG isolate suspended in medium-chain triglyceride oil.
Each participant received placebo and four escalating doses, 25, 50, 100, and 200 milligrams, with the placebo dose randomly placed within the ascending sequence and flavor and volume standardized to preserve blinding.
No drug-related adverse events occurred at any dose tested, including the highest, 200 milligrams, a dose well above what most commercial CBG products deliver per serving.
Liver function tests, checked at baseline and again after the two highest doses, never exceeded the upper limit of normal, an important reassurance for a compound taken orally and processed hepatically.
CBG produced few noticeable subjective or cognitive effects. Participants reported small decreases in self-rated Jittery and Active ratings after 50 milligrams, a decrease in Calm after 100 milligrams, and an increase in Appetite after 200 milligrams.
None of these changes describe an intoxicating or strongly psychoactive profile, which is consistent with how CBG is typically marketed, but the study was not designed to test whether these small pharmacodynamic shifts translate into any therapeutic benefit.
Plasma CBG concentrations increased in a dose-orderly fashion, meaning higher oral doses produced higher blood levels as expected.
The researchers also observed considerable variability between individuals in how much CBG appeared in plasma at a given dose, a finding with direct implications for how consistently patients might respond to a fixed commercial dose.
This was a single-dose, acute safety and pharmacokinetic study in 12 healthy adults. It was not designed to test whether CBG treats any condition, and it did not include repeated or chronic dosing, drug interaction testing, or a clinical patient population.
The authors themselves state that chronic dosing studies are needed to more fully characterize CBG’s safety and pharmacodynamic profile, a call this single study does not answer.
This trial builds on a small but growing body of controlled human CBG research, including an earlier placebo-controlled trial that found a single 20 milligram dose of CBG reduced self-reported anxiety and stress without intoxication. Together, these studies begin to sketch a safety and effect profile for a cannabinoid that has, until recently, been sold with far more marketing enthusiasm than human data behind it.
The authors are explicit that this single ascending-dose study is a foundational step, not a final answer, and that chronic dosing studies are the necessary next step before CBG’s safety and pharmacodynamic profile can be considered well characterized.
I welcome studies like this one. CBG has been sold to patients for years with far more confidence than the underlying human data supported, and a rigorously controlled academic safety and pharmacokinetic study, run by a group with real credibility in cannabinoid human-laboratory research, is exactly the kind of foundational evidence this field needs more of.
What I take from this is reassurance about acute tolerability at doses well above typical commercial servings, not a green light for any specific therapeutic claim. I would tell a patient that this study supports CBG’s short-term safety profile in healthy adults at these doses, and nothing more. Chronic use, drug interactions, and any real therapeutic benefit remain open questions that this study was never designed to answer.
How to Read a Small Safety Study Without Overselling It
A well-designed but small human laboratory study can be genuinely useful and easy to overstate at the same time.
Four checks keep this study’s real contribution, a foundational safety and pharmacokinetic profile, from being mistaken for proof of benefit.
A Four-Step Reading Frame
Confirm what was tested
Acute, single-dose safety and pharmacokinetics in healthy adults, not treatment of any condition.
Note the sample size
Twelve participants is enough to characterize acute tolerability, not enough to rule out rare effects.
Separate tolerability from benefit
CBG was well tolerated; that says nothing about whether it works for any marketed use.
Watch for the chronic-dosing follow-up
The authors themselves call this a first step; repeated-dose data is still missing.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
Reassuring on Safety, Silent on Benefit
If you are considering a commercial CBG product, this study offers real, controlled evidence that oral CBG was well tolerated in healthy adults at doses well above typical commercial servings, with no drug-related adverse events.
It does not tell you whether CBG will help with anxiety, sleep, or any other reason people take it, and it says nothing about regular, ongoing use.
A Baseline Worth Having, Not a Prescribing Guide
This study gives clinicians a controlled human data point on acute CBG tolerability and dosing, useful when patients ask about safety, but it does not establish an evidence-based indication or dosing protocol for any condition.
Patients with liver or kidney disease, those who are pregnant, and those on interacting medications were not studied here and should be counseled with that gap explicitly in mind.
Individual Variability Is the Real Headline for Dosing
The dose-orderly but individually variable pharmacokinetic profile means that a fixed milligram dose of CBG will not produce the same plasma exposure in every patient, a common feature of orally administered cannabinoids.
That variability has practical implications for anyone trying to standardize CBG dosing across a patient population, and it is exactly the kind of parameter that basic human pharmacokinetic studies exist to characterize.
Twelve People, One Dose, One Day
A sample of 12 healthy adults tested on a single occasion is enough to flag obvious acute safety problems, but it cannot rule out rarer adverse effects or characterize what happens with sustained use.
Marketing claims for CBG products routinely go well beyond what this study, or any current human CBG data, actually supports.
Regulation Still Lags the Market
CBG products are widely sold with therapeutic framing despite the near-total absence, until recently, of controlled human safety data, a gap this study begins to address.
Regulators and quality-standards bodies have limited independent safety data to draw on when evaluating commercial CBG products, which underscores why foundational studies like this one matter for future oversight.
Pharmaceutical-Grade Isolate Is Not the Same as What Is Sold
This study used a pharmaceutical-grade CBG isolate at precisely measured doses in a controlled laboratory setting, conditions that do not reflect the wide variability in purity, labeled-versus-actual potency, and formulation seen across commercial CBG products.
Patients using store-bought CBG products cannot assume the same dose accuracy or purity demonstrated in this study.
Precise Framing Protects Trust
Describing this as evidence that CBG safely treats anxiety, sleep problems, or any other condition would misrepresent a study that tested only acute tolerability and pharmacokinetics.
Accurately communicating what this study does and does not show helps preserve public trust in cannabinoid research as more rigorous human studies accumulate.
A First Step That Needs a Second One
The single ascending-dose design cannot address the question most patients actually care about: what happens with daily or regular CBG use over weeks or months, which is how these products are typically consumed.
The authors explicitly flag chronic dosing studies as the necessary next step, and until that data exists, this study’s findings should be understood as preliminary and acute-only.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved.
The 2024 CBG anxiety stress trial found that a single 20 mg dose of cannabigerol reduced anxiety and stress in healthy adults without intoxication. This placebo-controlled study provided the first controlled human evidence supporting CBG's anxiolytic potential, though with important caveats.
This digest entry noted early interest in CBD and CBG for metabolic and hepatic outcomes, offering earlier general context on CBG research directions.
Frequently Asked Questions
What did this study test?
A single ascending-dose, randomized, double-blind, placebo-controlled human laboratory study gave 12 healthy adults oral CBG isolate at 0 (placebo), 25, 50, 100, and 200 milligrams, measuring safety, subjective and cognitive effects, and plasma pharmacokinetics over 8 hours after each dose.
What is CBG?
Cannabigerol (CBG) is a minor, non-intoxicating cannabinoid found in the cannabis plant, increasingly sold in commercial wellness products, though controlled human research on its safety and effects has been limited until recently.
Was CBG safe in this study?
Yes, at the doses and single-dose exposure tested. No drug-related adverse events occurred at any dose up to 200 milligrams, and liver function tests stayed within normal limits even after the two highest doses.
Did CBG cause any noticeable effects?
Effects were minimal. Participants reported small decreases in self-rated Jittery and Active ratings at 50 milligrams, a decrease in Calm at 100 milligrams, and an increase in Appetite at 200 milligrams, but no strongly psychoactive or intoxicating effects were reported.
Does this study show CBG works for anxiety, sleep, or pain?
No. This study tested acute safety, tolerability, and pharmacokinetics only. It did not include any efficacy endpoint and does not support therapeutic claims for CBG.
How was CBG absorbed and processed in the body?
Plasma CBG concentrations rose in a dose-orderly way as the dose increased, but there was considerable variability between individuals, meaning the same milligram dose may not produce the same blood levels in every person.
Who conducted this research?
The study was conducted at the Behavioral Pharmacology Research Unit at Johns Hopkins University School of Medicine, with collaborators at the University of Maryland, University of Colorado, and University of Virginia, and published in the Journal of Pharmacology and Experimental Therapeutics.
How many people were in this study, and what are the limits of that?
Only 12 healthy adults were studied, on a single dosing occasion each. That is enough to flag obvious acute safety problems but not enough to rule out rarer effects or to say anything about repeated, long-term use.
Does this apply to the CBG products sold in stores?
Not directly. The study used a precisely measured, pharmaceutical-grade CBG isolate under controlled laboratory conditions, which does not reflect the variability in purity and labeled-versus-actual dose seen in many commercial CBG products.
What should someone considering a CBG product take from this study?
This study offers real, controlled reassurance about acute tolerability at doses well above typical commercial servings, but it does not establish that CBG is effective for any condition or that it is safe with regular, ongoing use. Discuss any CBG use with a treating clinician, especially if you have liver or kidney disease, are pregnant, or take interacting medications.
